This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient community care These data demonstrate Roche's commitment to providing options ...

LINE-1, a "jumping gene" making up 20% of the genome, invades DNA during cell division using protein-RNA clusters, offering ...

In CAR T-cell therapy for diffuse large B-cell lymphoma, distinct archetypes could guide personalized treatment decisions.

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three ...

The well-studied NF-κB signaling system is a key mediator of the inflammatory response. Large-scale sequencing studies in ...

Dog immune diseases attack blood cells. A study found sick dogs have a critical immune imbalance: fewer immune system brake ...

In the field of cancer immunotherapy, unconventional T cells (UCTs) and Chimeric Antigen Receptor (CAR) T cells have emerged as promising areas of research ...

Lyell Immunopharma announced new clinical data Tuesday from a Phase I/II trial of its dual-targeted CD19/CD20 CAR T-cell therapy for relapsed or refractory large B-cell lymphoma. The company ...

And yet, the key to saving these lives lies with the youth themselves. Patients have the best chance of survival when their ...